Covering mutually beneficial cooperation in the production of pharmaceutical products. The project is designed to support government policy on import substitution and affordable pharmaceuticals, and will optimize quality control and logistics of manufactured product.
Along with the plans for AKRIKHIN to manufacture finished pharmaceutical products with the use of active ingredients developed and produced by Aktivny Komponent, the partners have agreed to hold joint seminars and consultations and to work together on their technical, research, commercial and financial interactions with third parties.
Denis Chetverikov, President of AKRIKHIN, states:
“This signing of the letter of intent with Aktivny Komponent is a further concrete evidence of our contribution to import substitution and our commitment to interact with Russian producers of active pharmaceutical ingredients. We plan to start working jointly on new projects early next year and are confident that our partnership will continue to expand in terms of both scope and product volumes, with an exclusively positive long term impact on both our companies.”
Aktivny Komponent founder and President Alexander Semyonov pointed out:
“AKRIKHIN has been a reliable partner of ours for many years. Active ingredients supplied by Aktivny Komponent are used by this one of the leaders Russian pharmaceutical market in the production of popular medicines. We are happy to see a new level of our partnership that envisages our joint participation in projects to develop and manufacture pharmaceutical products in support of the import substitution goal.”
AKRIKHIN has already provided Aktivny Komponent with a list of active ingredients used to produce certain finished drugs. The company has also supplied information on anticipated demand for such ingredients over the next three years, along with a list of ingredients required for products, which still are in the plans for manufacturing.
The companies expect to reach full agreement on the details of their partnership and sign a corresponding agreement by February 2017.